The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

abstract：:Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

journal_title：Hematological oncology

authors： Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

更新日期：2015-12-01 00:00:00

abstract：:The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...

journal_title：Hematological oncology

authors： Scaggiante B,Dapas B,Pozzato G,Grassi G

更新日期：2013-06-01 00:00:00

abstract：:Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

journal_title：Hematological oncology

authors： Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

更新日期：2020-08-01 00:00:00

abstract：:Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...

journal_title：Hematological oncology

authors： Nwangwu CA,Weiher H,Schmidt-Wolf IGH

更新日期：2017-12-01 00:00:00

abstract：:Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

journal_title：Hematological oncology

authors： Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

更新日期：1989-11-01 00:00:00

abstract：:B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

journal_title：Hematological oncology

authors： Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

更新日期：2008-12-01 00:00:00

abstract：:Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...

journal_title：Hematological oncology

authors： Krashin E,Ellis M,Cohen K,Viner M,Neumark E,Rashid G,Ashur-Fabian O

更新日期：2018-04-01 00:00:00

abstract：:The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...

journal_title：Hematological oncology

authors： Peña C,Russo M,Martinez V,Cabrera ME

更新日期：2019-02-01 00:00:00

abstract：:Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...

journal_title：Hematological oncology

authors： Furlan C,Canzonieri V,Spina M,Michieli M,Ermacora A,Maestro R,Piccinin S,Bomben R,Dal Bo M,Trovo M,Gattei V,Tirelli U,Franchin G,Bulian P

更新日期：2017-12-01 00:00:00

abstract：:Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

journal_title：Hematological oncology

authors： Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

更新日期：2020-10-01 00:00:00

abstract：:Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...

journal_title：Hematological oncology

authors： Hussein S,Gill K,Baer LN,Hoehn D,Mansukhani M,Jobanputra V,Bhagat G,Alobeid B

更新日期：2015-03-01 00:00:00

abstract：:Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...

journal_title：Hematological oncology

authors： Woessmann W,Quintanilla-Martinez L

更新日期：2019-06-01 00:00:00

abstract：:We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...

journal_title：Hematological oncology

authors： Gobbi PG,Bergonzi M,Bassi E,Merli F,Coriani C,Federico M

更新日期：2013-09-01 00:00:00

abstract：:Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

journal_title：Hematological oncology

authors： Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

更新日期：2019-10-01 00:00:00

abstract：:Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...

journal_title：Hematological oncology

authors： Smith GM,Wright D,Child JA,Simmons AV,Norfolk DR,Barnard DL,Parker D,Parapia L

更新日期：1992-11-01 00:00:00

abstract：:In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

journal_title：Hematological oncology

authors： Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

更新日期：1999-12-01 00:00:00

abstract：:Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...

journal_title：Hematological oncology

authors： Gupta A,Punatar S,Gawande J,Bagal B,Mathew L,Bhat V,Kannan S,Khattry N

更新日期：2016-09-01 00:00:00

abstract：:There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

journal_title：Hematological oncology

authors： Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

更新日期：2013-03-01 00:00:00

abstract：:The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

journal_title：Hematological oncology

authors： Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

更新日期：1997-08-01 00:00:00

abstract：:For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...

journal_title：Hematological oncology

authors： Vaezi M,Bahar B,Mousavi A,Yaghmai M,Kasaeian A,Souri M,Jahani M,Alimoghaddam K,Ghavamzadeh A

更新日期：2017-03-01 00:00:00

abstract：:Intravascular lymphoma (IVL) is an extremely rare form of non-Hodgkin lymphoma characterized by almost exclusive growth of neoplastic lymphocytes within blood vessel lumen. IVL is morphologically characterized in most instances by large cells with B-cell lineage. IVL is an aggressive and usually disseminated disease t...

journal_title：Hematological oncology

authors： Ponzoni M,Ferreri AJ

更新日期：2006-09-01 00:00:00

abstract：:Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

journal_title：Hematological oncology

authors： Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

更新日期：2020-10-01 00:00:00

abstract：:There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

journal_title：Hematological oncology

authors： Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

更新日期：2019-08-01 00:00:00

abstract：:Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...

journal_title：Hematological oncology

authors： Martinelli G,Iacobucci I,Soverini S,Cilloni D,Saglio G,Pane F,Baccarani M

更新日期：2006-12-01 00:00:00

abstract：:Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

journal_title：Hematological oncology

authors： Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

更新日期：2017-09-01 00:00:00

abstract：:This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

journal_title：Hematological oncology

authors： Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

更新日期：2014-06-01 00:00:00

abstract：:Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard...

journal_title：Hematological oncology

authors： Bezinelli LM,de Paula Eduardo F,da Graça Lopes RM,Biazevic MG,de Paula Eduardo C,Correa L,Hamerschlak N,Michel-Crosato E

更新日期：2014-03-01 00:00:00

abstract：:This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

journal_title：Hematological oncology

authors： Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

更新日期：2008-12-01 00:00:00

abstract：:The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

journal_title：Hematological oncology

authors： Chetty R,Bickhoo A

更新日期：1997-11-01 00:00:00

abstract：:A retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty-five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow-up--43 months). Using multivariate...

journal_title：Hematological oncology

authors： Jeffery GM,Colls BM,Robinson BA,Fitzharris BM,Atkinson CH

更新日期：1989-09-01 00:00:00